Text Size

Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

This study has been completed.
Sponsor:
Information provided by:
Novo Nordisk
ClinicalTrials.gov Identifier:
NCT00124293
First received: June 30, 2005
Last updated: June 15, 2012
Last verified: January 2012
History of Changes
  Purpose

This study is conducted in North America. The purpose of this study is to evaluate the occurrence and severity of bleeding in brain injury and to identify important safety issues following traumatic brain injury.


Condition Intervention
Acquired Bleeding Disorder
Trauma
 Drug: activated recombinant human factor VII

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Multi Centre Observational Study to Evaluate the Incidence and Magnitude of Haemorrhagic Progression of Cerebral Contusions and the Identification of Important Safety Issues Following Traumatic Brain Injury

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Novo Nordisk:

Enrollment: 63
Study Start Date: October 2004
Study Completion Date: November 2005
Primary Completion Date: November 2005 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Factor VII Drug: activated recombinant human factor VII

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Subjects were selected from a speciality practice group (Neurosurgery practices with a focus on head trauma. Subjects will have had a mild-to-moderate head injury and require hospitalization.

Criteria

Inclusion Criteria:

  • Ages Eligible for Study: 18 Years - 85 Years
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00124293

  Show 20 Study Locations
Sponsors and Collaborators
Novo Nordisk
Investigators
Study Director: Brett Skolnick, PhD Novo Nordisk
  More Information

Additional Information:
Clinical Trials at Novo Nordisk  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Public Access to Clinical Trials, Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT00124293     History of Changes
Other Study ID Numbers: F7CBI-1587
Study First Received: June 30, 2005
Last Updated: June 15, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Blood Coagulation Disorders
Hemostatic Disorders
Hemorrhagic Disorders
Contusions
Hemorrhage
Brain Injuries
Hematologic Diseases
Vascular Diseases
Cardiovascular Diseases
 Wounds and Injuries
Wounds, Nonpenetrating
Pathologic Processes
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System

ClinicalTrials.gov processed this record on June 18, 2013